Technology ID

Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications

Lead Inventor
Zhi, Ning (NHLBI)
Young, Neal (NHLBI)
Kajigaya, Sachiko (NHLBI)
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available.
Lead IC
Parvovirus B19 (B19V) is the only known pathogenic human parvovirus. Infection by this viral pathogen can cause transient aplastic crisis in individuals with high red cell turnover, pure red cell aplasia in immunosuppressed patients, and hydrops fetalis during pregnancy. In children, B19V most commonly causes erythema infectiosum, or fifth's disease. Infection can also cause arthropathy and arthralgia. The virus is very erythrotropic, targeting human erythroid (red blood) progenitors found in the blood, bone marrow, and fetal liver. Currently, there are no approved vaccines or antiviral drugs for the treatment or prevention of B19V infection.

The subject technology is a series of plasmid constructs with codon optimized B19 viral capsid genes (VP1 and VP2) that can be expressed in mammalian cells. Transfection of vectors encoding these optimized VP1 and VP2 genes into different mammalian cell lines, including 293, Cos7, and Hela cells produce virus-like particles (VLPs). The vectors include bicistronic plasmids expressing the VP1 and VP2 proteins at different ratios to produce B19V VLPs with optimal antigenicity for vaccine applications. This technology can also be used for diagnostic applications and development of a viral packaging system for producing infectious B19V virus.
Commercial Applications
  • VLPs based vaccines for the prevention and/or treatment of B19V infection
  • DNA based vaccines for the prevention and/or treatment of B19V infection
  • B19V diagnostics
  • Viral packaging system
Competitive Advantages
  • Codon optimized VP1 and VP2 genes for better expression in mammalian cell lines
  • Expression of B19V VLPs from "nonpermissive" cell lines
Licensing Contact:
Choudhry, Vidita